The Food and Drugs Authority (FDA) of Ghana recently concluded a month-long study visit in partnership with the Global Health Policy Program (GHPP). This initiative brought together regulators from The Gambia, Liberia, and Sierra Leone for hands-on training in pharmaceutical regulation, aimed at enhancing public health systems across Africa.
FDA Ghana’s Chief Executive Officer, Dr. Delese Mimi Darko, welcomed the participants, reaffirming the Authority’s commitment to fostering collaboration. She emphasized that building strong regulatory frameworks is essential for safeguarding public health and urged continued partnerships to tackle Africa’s health challenges.
Practical Training and Impact
The training, led by FDA Ghana experts, focused on real-world application, ensuring that medicines across the region meet the highest standards. Participants praised the practical approach, with Musa from Sierra Leone highlighting the clarity and accessibility of the sessions.
Mr. Tijan Jallow, Director of Operations at The Gambia’s Medicines Control Agency, noted the transformative impact of the lab training. He commended FDA Ghana’s openness, which he believes will enhance public health outcomes across the region.
Regional Leadership
FDA Ghana’s role as a leader in regional public health was evident throughout the visit. The Authority’s commitment to sharing expertise has strengthened regulatory frameworks in the participating countries. Mr. Karikari-Boateng, Director of the FDA’s Center for Laboratory Services and Research, encouraged the trainees to maintain close ties with FDA Ghana as they apply their new skills.
Building Lasting Partnerships
The study visit has paved the way for stronger collaborations. Mrs. Andrea, the GHPP team lead, expressed gratitude for the partnership, emphasizing the importance of continued cooperation in achieving healthcare goals across Africa.
In a concluding reflection, Mr. Jallow stressed that no single country can combat public health challenges alone, underscoring the value of regional collaboration in minimizing risks associated with substandard medicines.
